177 related articles for article (PubMed ID: 17038522)
21. An IgG1 Version of the Anti-transferrin Receptor 1 Antibody ch128.1 Shows Significant Antitumor Activity Against Different Xenograft Models of Multiple Myeloma: A Brief Communication.
Daniels-Wells TR; Candelaria PV; Leoh LS; Nava M; Martínez-Maza O; Penichet ML
J Immunother; 2020; 43(2):48-52. PubMed ID: 31693515
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
[TBL] [Abstract][Full Text] [Related]
23. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
24. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.
Oflazoglu E; Stone IJ; Gordon KA; Grewal IS; van Rooijen N; Law CL; Gerber HP
Blood; 2007 Dec; 110(13):4370-2. PubMed ID: 17909075
[TBL] [Abstract][Full Text] [Related]
25. Role of the Fc region in CD70-specific antibody effects on cardiac transplant survival.
Shariff H; Greenlaw RE; Meader L; Gardner N; Yagita H; Coccia M; Mamode N; Jurcevic S
Transplantation; 2011 Dec; 92(11):1194-201. PubMed ID: 22089665
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.
Leoh LS; Kim YK; Candelaria PV; Martínez-Maza O; Daniels-Wells TR; Penichet ML
J Immunol; 2018 May; 200(10):3485-3494. PubMed ID: 29654211
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
29. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
30. A novel antibody-like TCRγδ-Ig fusion protein exhibits antitumor activity against human ovarian carcinoma.
Zheng J; Guo Y; Ji X; Cui L; He W
Cancer Lett; 2013 Dec; 341(2):150-8. PubMed ID: 23920126
[TBL] [Abstract][Full Text] [Related]
31. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.
Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q
FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558
[TBL] [Abstract][Full Text] [Related]
32. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia.
Vitale LA; He LZ; Thomas LJ; Widger J; Weidlick J; Crocker A; O'Neill T; Storey J; Glennie MJ; Grote DM; Ansell SM; Marsh H; Keler T
Clin Cancer Res; 2012 Jul; 18(14):3812-21. PubMed ID: 22589397
[TBL] [Abstract][Full Text] [Related]
33. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
Ring NG; Herndler-Brandstetter D; Weiskopf K; Shan L; Volkmer JP; George BM; Lietzenmayer M; McKenna KM; Naik TJ; McCarty A; Zheng Y; Ring AM; Flavell RA; Weissman IL
Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10578-E10585. PubMed ID: 29158380
[TBL] [Abstract][Full Text] [Related]
34. Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis.
Oflazoglu E; Boursalian TE; Zeng W; Edwards AC; Duniho S; McEarchern JA; Law CL; Gerber HP; Grewal IS
J Immunol; 2009 Sep; 183(6):3770-7. PubMed ID: 19710474
[TBL] [Abstract][Full Text] [Related]
35. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
[TBL] [Abstract][Full Text] [Related]
36. Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27.
Yoshino K; Kishibe K; Nagato T; Ueda S; Komabayashi Y; Takahara M; Harabuchi Y
Br J Haematol; 2013 Feb; 160(3):331-42. PubMed ID: 23206232
[TBL] [Abstract][Full Text] [Related]
37. Reciprocal expression of CD70 and of its receptor, CD27, in human long term-activated T and natural killer (NK) cells: inverse regulation by cytokines and role in induction of cytotoxicity.
Orengo AM; Cantoni C; Neglia F; Biassoni R; Ferrini S
Clin Exp Immunol; 1997 Mar; 107(3):608-13. PubMed ID: 9067541
[TBL] [Abstract][Full Text] [Related]
38. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
39. Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.
Zhang D; Armstrong AA; Tam SH; McCarthy SG; Luo J; Gilliland GL; Chiu ML
MAbs; 2017 Oct; 9(7):1129-1142. PubMed ID: 28758875
[TBL] [Abstract][Full Text] [Related]
40. Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.
Nagase-Zembutsu A; Hirotani K; Yamato M; Yamaguchi J; Takata T; Yoshida M; Fukuchi K; Yazawa M; Takahashi S; Agatsuma T
Cancer Sci; 2016 May; 107(5):674-81. PubMed ID: 26914241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
